A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I/II
Latest Information Update: 03 May 2019
Price : $35 *
At a glance
- Drugs CAB-ROR2-ADC (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BioAtla
- 28 Jun 2018 According to a Bioatla media release, first patient clinical study was enrolled and dosed at Sarah Cannon Research Institute at Tennessee Oncology in Nashville, TN under the direction of the principal investigator, Howard A.
- 12 Jun 2018 Status changed from not yet recruiting to recruiting.
- 19 Apr 2018 New trial record